



## ImmunoGen Announces Webcast of Presentation and Q&A at Upcoming Guggenheim Nantucket Therapeutics Conference

September 14, 2022

WALTHAM, Mass.--(BUSINESS WIRE)--Sep. 14, 2022-- [ImmunoGen, Inc.](#) (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Susan Altschuller, Chief Financial Officer, will participate in a fireside chat at the upcoming Guggenheim Nantucket Therapeutics Conference. The presentation is scheduled for September 28, 2022 at 11:15am ET.

A webcast of the presentation will be accessible through the "Investors and Media" section of the Company's website, [www.immunogen.com](http://www.immunogen.com). Following the live webcast, a replay will be available at the same location.

### ABOUT IMMUNOGEN

ImmunoGen is developing the next generation of antibody-drug conjugates to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, we aim to disrupt the progression of cancer and offer our patients more good days. We call this our commitment to TARGET A BETTER NOW™.

Learn more about who we are, what we do, and how we do it at [www.immunogen.com](http://www.immunogen.com).

View source version on [businesswire.com](https://www.businesswire.com/news/home/20220914005874/en/): <https://www.businesswire.com/news/home/20220914005874/en/>

### INVESTOR RELATIONS

ImmunoGen  
Anabel Chan  
781-895-0600  
[anabel.chan@immunogen.com](mailto:anabel.chan@immunogen.com)

### MEDIA

ImmunoGen  
Courtney O'Konek  
781-895-0600  
[courtney.okonek@immunogen.com](mailto:courtney.okonek@immunogen.com)

OR

FTI Consulting  
Robert Stanislaro  
212-850-5657  
[robert.stanislaro@fticonsulting.com](mailto:robert.stanislaro@fticonsulting.com)

Source: ImmunoGen, Inc.